Given that CD19 is co-expressed with GSDMD in pre-B cells, the combination of anti-CD19 CAR-T cells and TMEM173 agonists will hopefully magnify the efficiency of CAR-T cell therapies in B-ALL. Here, CD19 is linked to acute lymphoblastic leukemia.